SOP Individuelle Dosierung und Applikation von Antiinfektiva auf der Intensivstation

In dieser Rubrik stellen wir Standard Operating Procedures (SOPs) für häufige, intensivmedizinisch relevante Prozesse vor. Die Form ist eher im Sinne einer Schablone zu verstehen als – durchaus subjektiv gefärbte – Anregung, eigene, auf lokale Gegebenheiten adaptierte, stationsinterne SOPs zu entwerfen und zu implementieren.

• Literatur

• 1 Bloos F, Ruddel H, Thomas-Ruddel D. et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. Intensive Care Med 2017; 43: 1602-1612
• 2 Roberts JA, Abdul-Aziz MH, Lipman J. et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509
• 3 Brinkmann A, Röhr AC, Köberer A. et al. Adäquate Antiinfektivatherapie – Bedeutung der individuellen Dosierung und Applikation. Anaesthesist 2018; 67: 461-476
• 4 Brinkmann A, Röhr AC, Köberer A. et al. Therapeutisches Drug Monitoring und individualisierte Dosierung von Antibiotika bei der Sepsis – Modern oder nur „modisch“?. Med Klin Intensivmed Notfmed 2018; 113: 82-93
• 5 Richter DC, Heininger A, Brenner T. et al. Bakterielle Sepsis – Diagnostik und kalkulierte Antibiotikatherapie. Anaesthesist 2017; 66: 737-761
• 6 Roberts JA, Kumar A, Lipman J. Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. Crit Care Med 2017; 45: 331-336
• 7 Imani S, Buscher H, Marriott D. et al. Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother 2017; 72: 2891-2897
• 8 Paul-Ehrlich-Gesellschaft für Chemotherapie. S2k Leitlinie Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018. AWMF-Registernummer 082-006. Im Internet: https://www.awmf.org/uploads/tx_szleitlinien/S82-006l_S2k_Parenterale_Antibiotika_2018-1.pdf Stand: 29.06.2018
• 9 de With K, Allerberger F, Amann S. et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection 2016; 44: 395-439
• 10 Rhodes A, Evans LE, Alhazzani W. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017; 45: 486-552
• 11 Hanrahan T, Whitehouse T, Lipman J. et al. Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents 2015; 46: 249-253
• 12 Taubert M, Zander J, Frechen S. et al. Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens. J Antimicrob Chemother 2017; 72: 2304-2310
• 13 Lodise Jr TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-363
• 14 Abdul-Aziz MH, Sulaiman H, Mat-Nor MB. et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 2016; 42: 1535-1545
• 15 Roberts JA, Paul SK, Akova M. et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: Are current beta-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis 2014; 58: 1072-1083
• 16 Abdul-Aziz MH, Lipman J, Roberts JA. Antibiotic dosing for multidrug-resistant pathogen pneumonia. Curr Opin Infect Dis 2017; 30: 231-239
• 17 Abdul-Aziz MH, Lipman J, Akova M. et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother 2016; 71: 196-207
• 18 Abdul-Aziz MH, Lipman J, Mouton JW. et al. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 2015; 36: 136-153
• 19 Rhodes NJ, Liu J, OʼDonnell JN. et al. Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis. Crit Care Med 2018; 46: 236-243
• 20 Vardakas KZ, Voulgaris GL, Maliaros A. et al. Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 2018; 18: 108-120
• 21 Roberts JA, Abdul-Aziz MH, Davis JS. et al. Continuous versus intermittent β-Lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med 2016; 194: 681-691
• 22 Yang H, Zhang C, Zhou Q. et al. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. PLoS One 2015; 10: e0116769
• 23 Tafelski S, Nachtigall I, Trefzer T. et al. Evidenzbasiertes Antiinfektiva-Programm „ABx“ – Neue Möglichkeiten durch lokale Anpassung. Anasthesiol Intensivmed Notfallmed Schmerzther 2009; 44: 500-501
• 24 Dettli LC. Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974; 16: 274-280